经导管与外科干预:冠状动脉血运重建试验的启示
本文由心脏外科医生和介入心脏病学家共同撰写,从PCI/CABG试验中为TAVI/SAVR时代汲取教训。文章指出PCI和CABG均有效,但试验多聚焦于适合两种治疗的选定患者的「二选一」决策,对存在合并症或复杂病变的「真实世界」患者指导有限。试验设计需关注对照组意义、技术快速变迁、复合终点局限性、亚组分析角色及多学科心脏团队实施挑战等问题。
要点
- PCI/CABG试验多针对适合两种治疗的选定患者,对真实世界复杂患者指导有限。
- 复合终点如MACCE提供统计学显著性,但对患者导向需求洞察不足。
- TAVI/SAVR时代应从PCI/CABG试验中汲取教训,关注试验设计的临床相关性。
核心结论
- PCI和CABG均为有效治疗,但试验未能充分回答对真实世界患者的指导问题。
- TAVI/SAVR时代应从PCI/CABG试验的设计和解读问题中汲取教训。
研究设计与样本
- 本文为心脏外科医生与介入心脏病学家的述评,总结PCI/CABG试验的经验教训。
主要发现
- 试验聚焦于适合两种治疗的选定患者的「二选一」决策,对合并症或复杂病变患者指导有限。
- 复合终点如MACCE提供统计学显著性,但对患者导向需求洞察不足。
- 试验解读常聚焦Kaplan-Meier曲线上的相对获益,需仔细审视。
- 亚组分析在左室功能不全、糖尿病、多支病变和近端LAD狭窄等问题上常超出其应有角色。
- Meta分析存在争议,指南更新迅速且部分领域缺乏稳健证据。
临床怎么用
- 临床试验设计和解读应关注对照组的意义和相关性,以及真实世界患者的代表性。
- 多学科心脏团队会议已融入研究设计,但实践中实施具有挑战性。
局限性
- 试验常不能反映日常实践,如多支血管PCI、大量支架置入和全动脉化移植。
- 衰弱指标、血流生理测量、真实世界活动水平和获益预测在试验中罕见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this paper, a cardiac surgeon and an interventional cardiologist draw lessons from the trials of percutaneous coronary intervention/coronary artery bypass graft surgery (PCI/CABG) for the transcatheter aortic valve implantation/surgical aortic valve replacement (TAVI/SAVR) era. Both PCI and CABG are effective treatments, but do the trials ask the right questions? They dwell on the 'either/or' decision for selected patients suitable for both treatments, but provide little guidance for the majority of 'real world' patients with comorbidities precluding CABG, or complex coronary heart disease precluding PCI. The control group must be meaningful and relevant. The pace of technological and therapeutic change causes trials to date rapidly. Procedures often do not reflect everyday practice, such as performing multivessel PCI, copious stenting and full arterial grafting. Composite endpoints such as major adverse cardiovascular and cerebrovascular events (MACCE) provide statistical significance but little insight into patient-orientated needs. There is a variety of temporal, safety, symptomatic and prognostic endpoints, provoking debate over their relative and absolute magnitude and importance; and there are issues of interpretation and inappropriate extrapolation. Trial interpretation, crystallised in the Kaplan-Meier curve, focuses on the relative benefit of one treatment over another, but deserves careful scrutiny. Subgroup analysis tends to exceed its role in dealing with issues such as poor left ventricular function, diabetes, multivessel disease and proximal left anterior descending coronary artery stenosis. Meta-analysis is controversial and guidelines date rapidly, lacking robust evidence in some domains, yet assuming considerable importance. Measures of frailty, physiological measures of blood flow, 'real world' activity levels, and predictions of benefit rarely feature. The multidisciplinary Heart Team meeting, now integral to study design, is challenging to deliver in practice. The PCI/CABG trials, and the issues arising from them, provide salutary lessons in the TAVI/SAVR era.
引用
- Gunn J, Taggart DP. Transcatheter versus surgical intervention: lessons from trials of coronary revascularisation. Heart. 2019. PMID: 30846525. doi:10.1136/heartjnl-2018-313518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。